Intravenous immunoglobulin therapy in the treatment of BK viremia and nephropathy in pediatric renal transplant recipients

Pediatric Transplantation

Volumn 16, Issue 1, 2012, Pages

  Anyaegbu, E I ^a   Almond, P S ^a   Milligan, T ^a   Allen, W R ^a   Gharaybeh, S ^a   Al Akash, S I ^a  

^a DRISCOLL CHILDREN S HOSPITAL   (United States)

Author keywords

IVIG; pediatric transplantation; polyoma BK virus; polyoma associated nephropathy

Indexed keywords

DACLIZUMAB; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ARTICLE; BK VIRUS; CASE REPORT; CHILD; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; NEPHROTIC SYNDROME; NONHUMAN; PERSISTENT VIRUS INFECTION; RECIPIENT; RENAL GRAFT DYSFUNCTION; SCREENING; VIREMIA; VIRUS DETECTION; VIRUS LOAD;

ADOLESCENT; BK VIRUS; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; POLYOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIREMIA;

EID: 84856020183     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2010.01384.x     Document Type: Article

References (29)

1. Acott PD, Hirsch HH,. BK virus infection, replication, and diseases in pediatric kidney transplantation. Pediatr Nephrol 2007: 22: 1243-1250. (Pubitemid 47054911)
2. Schold JD, Rehman S, Kayle LK, Magliocca J, Srinivas TR, Meier-Kriesche HU,. Treatment for BK virus: Incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009: 22: 626-634.
3. Smith JM, Mcdonald RA, Finn LS, Healey PJ, Davis CL, Limaye AP,. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004: 4: 2109-2117. (Pubitemid 39611641)
4. Ginevri F, Azzi A, Hirsch HH, et al., Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007: 7: 2727-2735. (Pubitemid 350045762)
5. Bohl DL, Storch GA, Ryschkewitsch C, et al., Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant 2005: 5: 2213-2221. (Pubitemid 41648468)
6. Lamoth F, Pascual M, Erard V, Venetz JP, Nseir G, Meylan P,. Low-dose cidofovir for the treatment of polyomavirus-associated nephropathy: Two case reports and review of the literature. Antivir Ther 2008: 13: 1001-1009.
7. Wu SW, Horng-Rong C, Lian J,. The effect of low-dose cidofovir on the long term outcome of polyomavirus-associated nephropathy in renal transplant recipients. Nephrol Dial Transplant 2009: 24: 1034-1038.
8. Kadambi PV, Josephson MA, Williams J, et al., Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 2003: 3: 186-191. (Pubitemid 36323116)
9. Teschner S, Gerke P, Gever M, et al., Leflunomide therapy for polyomavirus-induced allograft nephropathy: Efficient BK virus elimination without increased risk of rejection. Transplant Proc 2009: 41: 2533-2538.
10. Leca N, Muczynski KA, Jefferson JA, et al., Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients. Clin J Am Soc Nephrol 2008: 3: 829-835.
11. Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA,. Treatment of polyomavirus infection in kidney transplant recipients: A systematic review. Transplantation 2010: 89: 1057-1070.
12. Jordan SC, Tyan D, Czer L, Toyoda M,. Immunoodulatory actions of intravenous actions of intravenous immunoglobulins (IVIG): Potential applications in applications in solid organ transplant recipients. Pediatr Transplant 1998: 2: 92-105. (Pubitemid 128655513)
13. Casadei DH, Del C Rial M, Opelz G, et al., A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001: 71: 53-58. (Pubitemid 32105778)
14. Jordan SC, Tyan D, Stablein D, et al., Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly-HLA sensitized adult patients with end stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004: 15: 3256-3262. (Pubitemid 39578859)
15. Vo AA, Lukovsky M, Toyoda M, et al., Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008: 359: 242-251. (Pubitemid 352008439)
16. Sharma AP, Moussa M, Casier S, Rehman F, Filler G, Grimmer J,. Intravenous immunoglobulin as rescue therapy for BK virus nephropathy. Pediatr Transplant 2009: 13: 123-129.
17. Sener A, House AA, Jevnikar AM, et al., Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: One-year follow-up of renal allograft recipients. Transplantation 2006: 81: 117-120. (Pubitemid 43122158)
18. Halim MA, Al-Otaibi T, El-Kholy O, et al., Active management of post-renal transplantation BK virus nephropathy: Preliminary report. Transplant Proc 2009: 41: 2850-2852.
19. Hardinger KL, Koch MJ, Bohl DJ, Storch GA, Brennan DC,. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant 2010: 10: 407-415.
20. Hirsch HH, Randhawa P,. BK virus in solid organ transplant recipients. Am J Transplant 2009: 9 (Suppl. 4): S136-S146.
21. Smith JM, Dharnidharka VR, Talley L, Martz K, Mcdonald RA,. BK nephropathy in pediatric renal transplant recipients: An analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2007: 2: 1037-1042.
22. Andrei G, Snoeck R, Vandeputte M, De Clerc E,. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997: 41: 587-593. (Pubitemid 27098409)
23. Bernhoff E, Gutteberg TJ, Sandvik K, Hirsch HH, Rinaldo CH,. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant 2008: 8: 1413-1422. (Pubitemid 351989495)
24. De Luca A, Giancola ML, Ammassari A, et al., A Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. AIDS 2000: 14: F117-F121.
25. Kuypers DRJ, Bammens B, Claes K, Evenepoel P, Lerut E, Vanrenterghem Y,. A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipients. J Antimicrob Ther 2009: 63: 417-419.
26. Araya CE, Garin EH, Neiberger RE, Dharnidharka VR,. Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients. Pediatr Transplant 2010: 14: 145-150.
27. Faguer S, Hirsch HH, Kamar N, et al., Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 2007: 20: 962-969. (Pubitemid 47537566)
28. Williams JW, Javaid B, Kadambi PV, et al., Leflunomide for Polyomavirus type BK nephropathy. N Engl J Med 2005: 352: 1157-1158.
29. Puliyanda D, Radha RK, Amet N, et al., IVIG contains antibodies reactive with polyoma BK virus and may represent a therapeutic option for BK nephropathy. Am J Transplant 2003: 3 (Suppl. 5): 393.